Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D).
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: University of Washington, Janssen Research & Development (United States), Hospital Del Mar, Municipal Institute for Medical Research, Hospital del Mar Research Institute, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, National and Kapodistrian University of Athens, Memorial Sloan Kettering Cancer Center, Royal Marsden NHS Foundation Trust, Institute of Cancer Research
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2604664482